Deferasiroxisanironchelatorcommonlyusedtotreatiron-overloaddisease.Deferasiroxalsodisplaysbothneuroprotectiveandchemotherapeuticbenefitaswell.Thiscompoundexhibitsneuroprotectiveactivityinbothinvitroandinvivomodelsofstroke/ischemiaconditions.Invitro,deferasiroxincreasesexpressionofmetastasissuppressinggenes,p21,caspase-3,andPARPanddecreaseslevelsofcyclinD1andactivityofNF-κB.TheABIlityofdeferasiroxtoinhibitironuptakedecreasestumorgrowthinanimalmodelsofcancer.
| CasNo. | 201530-41-8 |
|---|---|
| Purity | ≥98% |
| Formula | C21H15N3O4 |
| FormulaWt. | 373.63 |
| ChemicalName | 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoicAcid |
| IUPACName | 4-[(3Z,5E)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoicacid |
| Synonym | ICL670A,CGP72670 |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| MSDS | D1621MSDSPDF |
|---|---|
| InfoSheet | D1621InfoSheetPDF |
Vazana-BaradL,GranotG,Mor-TzuntzR,etal.Mechanismoftheantitumoralactivityofdeferasirox,anironchelationagent,onmantlecelllymphoma.LeukLymphoma.2013Apr;54(4):851-9.PMID:23020673.
LuiGY,ObeidyP,FordSJ,etal.Theironchelator,deferasirox,asanovelstrategyforcancertreatment:oralactivityagainsthumanlungtumorxenograftsandmolecularmechanismofaction.MolPharmacol.2013Jan;83(1):179-90.PMID:23074173.
ZhaoY,RempeDA.Prophylacticneuroprotectionagainststroke:low-dose,prolongedtreatmentwithdeferoxamineordeferasiroxestablishesprolongedneuroprotectionindependentofHIF-1function.JCerebBloodFlowMetab.2011Jun;31(6):1412-23.PMID:21245873.
MessaE,CarturanS,MaffèC,etal.DeferasiroxisapowerfulNF-kappaBinhibitorinmyelodysplasticcellsandinleukemiacelllinesactingindependentlyfromcellirondeprivationbychelationandreactiveoxygenspeciesscavenging.Haematologica.2010Aug;95(8):1308-16.PMID:20534700.
LindseyWT,OlinBR.Deferasiroxfortransfusion-relatedironoverload:aclinicalreview.ClinTher.2007Oct;29(10):2154-66.PMID:18042472.
